

CORRECTION

Open Access



Correction to: Heregulin β 1 drives gefitinib-resistant growth and invasion in tamoxifen-resistant MCF-7 breast cancer cells

Iain R. Hutcheson^{1*}, Janice M. Knowlden¹, Steve E. Hiscox¹, Denise Barrow¹, Julia M. W. Gee¹, John F. Robertson², Ian O. Ellis² and Robert I. Nicholson¹

Correction

After the publication of this work [1], an error was noticed in Fig. 2b and Fig. 4b as well as Fig. 5d. and Fig. 5d. Images of the ERK1/2 blots were accidentally duplicated. In Fig. 5a. and Fig. 5c., the last lane for p-ERK1/2 was mistakenly cropped out of the final image. The original blot for Fig. 4b., “total EGFR” (or lane 2) is shown below to avoid any misunderstanding of the data. We apologize for this error, which did not affect any of the interpretations or conclusions of the article.

Fig. 4b. Uncropped original blot of “total EGFR” suggests that total EGFR levels increase with gefitinib treatment. However, increases in EGFR expression in response to gefitinib, are not seen across the study, which would suggest this increase is simply an anomaly.

Author details

¹Tenovus Centre for Cancer Research, Welsh School of Pharmacy, Cardiff University, Redwood Building, King Edward VII Avenue, Cardiff CF10 3XF, UK.

²Professorial Unit of Surgery, Nottingham City Hospital, Hucknall Road, Nottingham NG5 1PB, UK.

Received: 6 June 2018 Accepted: 6 June 2018

Published online: 30 August 2018

Reference

1. Nicholson IR, et al. Heregulin β 1 drives gefitinib-resistant growth, and invasion in tamoxifen-resistant MCF-7 breast cancer cells. *Breast Cancer Res.* 2007;9(4):R50.

* Correspondence: hutchesonir@cf.ac.uk

¹Tenovus Centre for Cancer Research, Welsh School of Pharmacy, Cardiff University, Redwood Building, King Edward VII Avenue, Cardiff CF10 3XF, UK

